Guifu Dihuang Pills Ameliorated Mucus Hypersecretion by Suppressing Muc5ac Expression and Inactivating the ERK-SP1 Pathway in Lipopolysaccharide/Cigarette Smoke-Induced Mice

Mucus hypersecretion is a hallmark of chronic obstructive pulmonary disease (COPD) and is associated with increasing sputum production and declining pulmonary function. Therefore, reducing mucus secretion can be a new therapeutic opportunity for preventing COPD. The Guifu Dihuang pill (GFDHP) is a c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huanhuan Zhang, Wenying Yu, Liting Ji, Yusen Zhong, Yiyou Lin, Huazhong Ying, Chenhuan Yu, Changyu Li
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Other systems of medicine RZ201-999
Acceso en línea:	https://doaj.org/article/2cd966e7d80644079f24bc378f97392c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2cd966e7d80644079f24bc378f97392c
record_format	dspace
spelling	oai:doaj.org-article:2cd966e7d80644079f24bc378f97392c2021-11-15T01:19:37ZGuifu Dihuang Pills Ameliorated Mucus Hypersecretion by Suppressing Muc5ac Expression and Inactivating the ERK-SP1 Pathway in Lipopolysaccharide/Cigarette Smoke-Induced Mice1741-428810.1155/2021/9539218https://doaj.org/article/2cd966e7d80644079f24bc378f97392c2021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/9539218https://doaj.org/toc/1741-4288Mucus hypersecretion is a hallmark of chronic obstructive pulmonary disease (COPD) and is associated with increasing sputum production and declining pulmonary function. Therefore, reducing mucus secretion can be a new therapeutic opportunity for preventing COPD. The Guifu Dihuang pill (GFDHP) is a classical Chinese medicine and has been used as an immunoregulator for treatment of kidney yang deficiency syndrome, including hypothyroidism, adrenocortical hypofunction, chronic bronchitis, and COPD, for more than 2000 years. However, the protective effects and mechanisms of GFDHP against mucus hypersecretion in COPD remain obscure. The aim of the present study was to explore the inhibitory effects of GFDHP on lipopolysaccharide/cigarette smoke- (LPS/CS-) induced Mucin5ac (Muc5ac) overproduction and airway goblet cell hyperplasia in mice. The mice were randomly assigned into 6 groups: control, model, GFDHP-L, GFDHP-M, GFDHP-H, and dexamethasone. The mice were given LPS twice through intranasal inhalation and then exposed to CS daily for 6 weeks. Three doses of GFDHP were orally administered daily during the last 3 weeks of the experiment. Pulmonary function was examined with an EMKA pulmonary system, and pulmonary hyperpermeability and lung damage were evaluated with an in vivo imaging system. Inflammatory cells and cytokines in bronchoalveolar lavage fluid (BALF) were detected with a cell count analyzer and though ELISA analysis, respectively. Lung pathological changes and airway goblet cell hyperplasia were analyzed with hematoxylin and eosin and Alcian blue periodic acid Schiff staining. The protein expression levels of Muc5ac and extracellular signal-regulated kinase (ERK)-specificity protein1 (SP1) signaling pathway were measured with Western blot and immunohistochemistry. The results demonstrated that GFDHP improved pulmonary function and suppressed mouse pulmonary hyperpermeability and edema. GFDHP suppressed inflammatory cell infiltration and cytokine release in BALF, thereby elevating pulmonary function. It ameliorated lung pathological changes and airway goblet cell hyperplasia, and suppressed expression levels of Muc5ac mRNA and protein and phospho-ERK and SP1 levels in the lung tissues of the COPD mice. In conclusion, GFDHP inhibited mucus hypersecretion induced by LPS/CS by suppressing the activation of the ERK-SP1 pathway.Huanhuan ZhangWenying YuLiting JiYusen ZhongYiyou LinHuazhong YingChenhuan YuChangyu LiHindawi LimitedarticleOther systems of medicineRZ201-999ENEvidence-Based Complementary and Alternative Medicine, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Other systems of medicine RZ201-999
spellingShingle	Other systems of medicine RZ201-999 Huanhuan Zhang Wenying Yu Liting Ji Yusen Zhong Yiyou Lin Huazhong Ying Chenhuan Yu Changyu Li Guifu Dihuang Pills Ameliorated Mucus Hypersecretion by Suppressing Muc5ac Expression and Inactivating the ERK-SP1 Pathway in Lipopolysaccharide/Cigarette Smoke-Induced Mice
description	Mucus hypersecretion is a hallmark of chronic obstructive pulmonary disease (COPD) and is associated with increasing sputum production and declining pulmonary function. Therefore, reducing mucus secretion can be a new therapeutic opportunity for preventing COPD. The Guifu Dihuang pill (GFDHP) is a classical Chinese medicine and has been used as an immunoregulator for treatment of kidney yang deficiency syndrome, including hypothyroidism, adrenocortical hypofunction, chronic bronchitis, and COPD, for more than 2000 years. However, the protective effects and mechanisms of GFDHP against mucus hypersecretion in COPD remain obscure. The aim of the present study was to explore the inhibitory effects of GFDHP on lipopolysaccharide/cigarette smoke- (LPS/CS-) induced Mucin5ac (Muc5ac) overproduction and airway goblet cell hyperplasia in mice. The mice were randomly assigned into 6 groups: control, model, GFDHP-L, GFDHP-M, GFDHP-H, and dexamethasone. The mice were given LPS twice through intranasal inhalation and then exposed to CS daily for 6 weeks. Three doses of GFDHP were orally administered daily during the last 3 weeks of the experiment. Pulmonary function was examined with an EMKA pulmonary system, and pulmonary hyperpermeability and lung damage were evaluated with an in vivo imaging system. Inflammatory cells and cytokines in bronchoalveolar lavage fluid (BALF) were detected with a cell count analyzer and though ELISA analysis, respectively. Lung pathological changes and airway goblet cell hyperplasia were analyzed with hematoxylin and eosin and Alcian blue periodic acid Schiff staining. The protein expression levels of Muc5ac and extracellular signal-regulated kinase (ERK)-specificity protein1 (SP1) signaling pathway were measured with Western blot and immunohistochemistry. The results demonstrated that GFDHP improved pulmonary function and suppressed mouse pulmonary hyperpermeability and edema. GFDHP suppressed inflammatory cell infiltration and cytokine release in BALF, thereby elevating pulmonary function. It ameliorated lung pathological changes and airway goblet cell hyperplasia, and suppressed expression levels of Muc5ac mRNA and protein and phospho-ERK and SP1 levels in the lung tissues of the COPD mice. In conclusion, GFDHP inhibited mucus hypersecretion induced by LPS/CS by suppressing the activation of the ERK-SP1 pathway.
format	article
author	Huanhuan Zhang Wenying Yu Liting Ji Yusen Zhong Yiyou Lin Huazhong Ying Chenhuan Yu Changyu Li
author_facet	Huanhuan Zhang Wenying Yu Liting Ji Yusen Zhong Yiyou Lin Huazhong Ying Chenhuan Yu Changyu Li
author_sort	Huanhuan Zhang
title	Guifu Dihuang Pills Ameliorated Mucus Hypersecretion by Suppressing Muc5ac Expression and Inactivating the ERK-SP1 Pathway in Lipopolysaccharide/Cigarette Smoke-Induced Mice
title_short	Guifu Dihuang Pills Ameliorated Mucus Hypersecretion by Suppressing Muc5ac Expression and Inactivating the ERK-SP1 Pathway in Lipopolysaccharide/Cigarette Smoke-Induced Mice
title_full	Guifu Dihuang Pills Ameliorated Mucus Hypersecretion by Suppressing Muc5ac Expression and Inactivating the ERK-SP1 Pathway in Lipopolysaccharide/Cigarette Smoke-Induced Mice
title_fullStr	Guifu Dihuang Pills Ameliorated Mucus Hypersecretion by Suppressing Muc5ac Expression and Inactivating the ERK-SP1 Pathway in Lipopolysaccharide/Cigarette Smoke-Induced Mice
title_full_unstemmed	Guifu Dihuang Pills Ameliorated Mucus Hypersecretion by Suppressing Muc5ac Expression and Inactivating the ERK-SP1 Pathway in Lipopolysaccharide/Cigarette Smoke-Induced Mice
title_sort	guifu dihuang pills ameliorated mucus hypersecretion by suppressing muc5ac expression and inactivating the erk-sp1 pathway in lipopolysaccharide/cigarette smoke-induced mice
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/2cd966e7d80644079f24bc378f97392c
work_keys_str_mv	AT huanhuanzhang guifudihuangpillsamelioratedmucushypersecretionbysuppressingmuc5acexpressionandinactivatingtheerksp1pathwayinlipopolysaccharidecigarettesmokeinducedmice AT wenyingyu guifudihuangpillsamelioratedmucushypersecretionbysuppressingmuc5acexpressionandinactivatingtheerksp1pathwayinlipopolysaccharidecigarettesmokeinducedmice AT litingji guifudihuangpillsamelioratedmucushypersecretionbysuppressingmuc5acexpressionandinactivatingtheerksp1pathwayinlipopolysaccharidecigarettesmokeinducedmice AT yusenzhong guifudihuangpillsamelioratedmucushypersecretionbysuppressingmuc5acexpressionandinactivatingtheerksp1pathwayinlipopolysaccharidecigarettesmokeinducedmice AT yiyoulin guifudihuangpillsamelioratedmucushypersecretionbysuppressingmuc5acexpressionandinactivatingtheerksp1pathwayinlipopolysaccharidecigarettesmokeinducedmice AT huazhongying guifudihuangpillsamelioratedmucushypersecretionbysuppressingmuc5acexpressionandinactivatingtheerksp1pathwayinlipopolysaccharidecigarettesmokeinducedmice AT chenhuanyu guifudihuangpillsamelioratedmucushypersecretionbysuppressingmuc5acexpressionandinactivatingtheerksp1pathwayinlipopolysaccharidecigarettesmokeinducedmice AT changyuli guifudihuangpillsamelioratedmucushypersecretionbysuppressingmuc5acexpressionandinactivatingtheerksp1pathwayinlipopolysaccharidecigarettesmokeinducedmice
_version_	1718428913319804928

Guifu Dihuang Pills Ameliorated Mucus Hypersecretion by Suppressing Muc5ac Expression and Inactivating the ERK-SP1 Pathway in Lipopolysaccharide/Cigarette Smoke-Induced Mice

Ejemplares similares